Document |
Document Title |
WO/2023/220715A1 |
The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutica...
|
WO/2023/219456A1 |
The present invention relates to a quinoline derivative, a preparation method therefor, and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of cancer, autoimmune diseases, fibrosis, and...
|
WO/2023/214317A1 |
Provided herein a method for treating or preventing a protein misfolding and deposition disease in a subject, by administering to the subject a low dose amount of compound (1). Provided herein is also a method for reversing or preventing...
|
WO/2023/215277A1 |
The present disclosure relates to trimeprazine for use in methods of treating trigeminal neuralgia and pain related thereto, by administering to a patient in need thereof a therapeutically effective amount of trimeprazine. The methods ma...
|
WO/2018/228692A9 |
The invention provides Cav2.3 R-type voltage gated calcium channel (coded by the CACNA1E gene) antagonists for the treatment and for use in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and pharmaceutica...
|
WO/2023/213850A1 |
The present invention relates to a compound and pharmaceutical compositions thereof for use in preventing or treating a tauopathy.
|
WO/2023/214833A1 |
The present invention relates to a fusion protein comprising GLP-1, immunoglobulin Fc, and IGF-1, and use thereof. The fusion protein of the present invention has excellent efficiency in blood-brain barrier permeability, and thus can be ...
|
WO/2023/215133A1 |
The present invention relates to compounds of formula (I) useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PlKfyve) as well as their use for treating diseases and disorders associated with PlKfyve.
|
WO/2023/215266A1 |
BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for e...
|
WO/2023/214285A1 |
The disclosure presented herein provides methods for treating a subject suffering from a pathological condition. The method is based on a fast desensitization protocol comprising intradermal injection of female sexual hormones. Further d...
|
WO/2023/213198A1 |
The present invention provides the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, or metabolite thereof, and a pharmaceutical composition containing the compound of the present inventio...
|
WO/2023/214838A1 |
The present invention relates to novel isoquinoline derivatives. The derivatives have an effect of promoting mitophagy activity, thereby reducing mitochondria with structural and/or functional damage. In particular, the novel isoquinolin...
|
WO/2023/212811A1 |
This disclosure relates to heterocyclic compounds of Formula (I). As contemplated herein, heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorder...
|
WO/2023/215377A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including neuroinflammatory diseases.
|
WO/2023/213902A1 |
The invention relates to remofuscin for use against aging, lysomal dysfunction, for use in stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, and for use in increasing the expression levels of th...
|
WO/2023/215443A1 |
Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.
|
WO/2023/214778A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating degenerative brain disease, comprising at least one of an anti-CD300c antibody and an antigen-binding fragment thereof; a method for preventing or ...
|
WO/2023/214189A1 |
Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in...
|
WO/2023/215787A1 |
Provided are anti-syndecan-2 antibodies or antigen binding fragments thereof, as well as compositions comprising said antibody or antigen binding fragment thereof and methods useful for treating diseases associated with syndecan-2 mediat...
|
WO/2023/215342A1 |
As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin. The present disclosure also features methods for treating or preventing trigeminal neuralgia, symptoms thereof, and/or tri...
|
WO/2023/213264A1 |
The present invention relates to a novel oleanamide derivative for activating a KEAP/NRF2/ARE signaling pathway. The compound of the present invention is represented by general formula (I), wherein L, R3, R4, Z, and n are set forth in th...
|
WO/2023/213739A1 |
Compounds of general formula (I), pharmaceutical compositions comprising the compound, uses of the compositions, and methods of manufacturing the compound are disclosed. The compounds are nicotinic acetylcholine receptor (nAChR) ligands,...
|
WO/2023/213740A1 |
FTR3159/PCT (P/85142.WO01) - 74 - NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Abstract Compounds of general formula (I), pharmaceutical compositions comprising the compound, uses of the compositions, and methods of manufacturing the compoun...
|
WO/2023/213279A1 |
Provided in the present invention are a piperidine derivative, a preparation method therefor, and a use thereof, relating to the chemical and pharmaceutical technical fields. The piperidine derivative is a compound represented by formula...
|
WO/2023/215467A1 |
Provided herein are compositions and methods of delivering nucleic acids, such as therapeutic mRNAs and DNA, to the central nervous system by delivery, e.g., intrathecally or intracerebrally, of nucleic acid containing lipid nanoparticle...
|
WO/2023/214836A1 |
The present invention relates to a novel berberine analogue CD1-410. It has been identified that the novel berberine analogue promotes the activity of mitophagy, and thus can reduce mitochondria with a damaged structure and/or function. ...
|
WO/2023/213854A1 |
Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylat
e.
|
WO/2023/215595A1 |
The present disclosure is directed to methods of effectively treating or preventing anxiety disorders, e.g., social anxiety disorder, with pharmaceutical compositions comprising at least one cannabinoid, as well as methods of making and ...
|
WO/2023/215697A1 |
Multispecific binding molecules having a first binding domain targeting a blood brain barrier target and a second binding domain targeting a neuron target, astrocyte target and / or glial cell target, and uses thereof in aiding the treat...
|
WO/2023/214404A1 |
A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having diffe...
|
WO/2023/214391A1 |
Compositions and methods for treating a cancer or a neurological disease. A method of treating a cancer or a neurological disease comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin...
|
WO/2023/214119A1 |
The present disclosure relates to compounds of formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, wherein R1 to R9 are as defined in the claims. Further is disclosed compounds of formula (I) for use in the treat...
|
WO/2023/215376A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including neuropathies.
|
WO/2023/214091A1 |
The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that ...
|
WO/2023/215338A1 |
As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin. The present disclosure also features methods for treating or preventing cluster headache, symptoms thereof, and/or cluster...
|
WO/2023/215455A1 |
The present application relates to a composition suitable for treating glial-mediated neurodegenerative disease or glial-mediated neuropsychiatric disease comprising a population of isolated human microglial progenitor cells derived from...
|
WO/2023/214772A1 |
The present invention relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory a...
|
WO/2023/214172A1 |
The present invention relates to crystalline forms of 6-hydroxy cannabidivarin (6-OH CBDV), methods for their production, and their use in therapy. The crystalline forms are easier to handle than other solid forms, such as glass amorphou...
|
WO/2023/213836A1 |
The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compos...
|
WO/2023/214282A1 |
Provided is a composition comprising at least one terpene for use in modulation of a physiological function via at least one selected from the group consisting of agonism of a cannabinoid type 1 receptor (CB1R), modulation of agonism of ...
|
WO/2023/210811A1 |
An oral composition comprising: an inorganic porous material having an average particle size of 60 μm or more, as a base material; and nicotine, wherein, in the inorganic porous material, the pore volume of pores having a pore size not ...
|
WO/2023/207730A1 |
Disclosed in the present application is an R-ketamine liquid preparation. The R-ketamine liquid preparation is an aqueous solution preparation, and comprises R-ketamine or a pharmaceutically acceptable salt thereof, a pharmaceutically ac...
|
WO/2023/210233A1 |
The present invention addresses the problem of providing a technique for effectively exerting the activity of a polynucleotide in the brain. The problem is solved by a compound represented by general formula (1) [In the formula, Ms repre...
|
WO/2023/211779A1 |
The present invention relates to a method for treating or preventing headache disorders selected from the group consisting of migraine, medication overuse headache, cluster headache, general headache, trigeminal neuralgia, and orofacial ...
|
WO/2023/212531A1 |
The disclosure relates to methods of nerve repair utilizing polyethylene glycol (PEG) to fuse severed axons after injury. This approach does not depend upon the natural regeneration of injured nerves and thus can be applied to spinal cor...
|
WO/2023/210405A1 |
This variant neurodegenerative disease-associated protein comprises an amino acid sequence in which one or several amino acids present in a region of interaction between two protofilaments (PF) among the amino acid sequences of the neuro...
|
WO/2023/210767A1 |
Provided is a new technology for a chemical ligation reaction of oligonucleotides. When 2'-fluoro-5'-amino-nucleic acid (2F-5N nucleic acid) having a fluorine atom at the 2'-positon of 5'-amino-nucleic acid (5N nucleic acid) is synthesiz...
|
WO/2023/208865A1 |
There is disclosed a compound of Formula (II), a method of manufacturing thereof as well as uses thereof.
|
WO/2023/211684A2 |
A method for the prevention and/or treatment of post-operative cognitive dysfunction, which entails administering to a human or other mammal an effective amount of one or more compounds selected from the group consisting of N-substituted...
|
WO/2023/210481A1 |
A composition for treating or preventing respiratory diseases, a composition for improving sleep or promoting sleep onset, a composition for reducing fatigue, a composition for improving complexion, a composition for improving skin textu...
|